During the previous decades, numerous genetic variations have been described in NSCLC, including epidermal growth factor receptor (EGFR), KRAS and anaplastic lymphoma kinase (ALK), as the most commonly altered oncogenes acting as tumor driver genes.6 This evidence concerns the gene EGFR and neoplasm.